Paper Review Records
All Paper Review Records
17 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
114
days
A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma
AuthorsRicardo Ahrens; Kyra Ahrens; Maximilian Al-Bazaz; Lisa Leypoldt; Carsten Bokemeyer; Winfried Alsdorf; Katja Weisel
Affiliations1. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2. Knowledge Technology Group, Department of Informatics, University of Hamburg, Hamburg, Germany
79
days
Clinicomolecular features and clonal evolution of KMT2A -PTD AML: prognostic impact of concurrent FLT3 -ITD under 2022 ELN risk stratification
AuthorsYi-Tsung Yang; Chi-Yuan Yao; Yong-Huai Yi; Chein-Jun Kao; Yuan-Yeh Kuo; Ming-En Lin; Hsin-An Hou; Chien-Chin Lin; Wen-Chien Chou; Hwei-Fang Tien
Affiliations1. Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 2. Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; 3. Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; 4. Tai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan; 5. Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan; 6. Department of Internal Medicine, Far-Eastern Memorial Hospital, New Taipei City, Taiwan
116
days
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
AuthorsMansi R. Shah; Aishee Bag; Asis Shrestha; Yetunde Ogunsesan; Anup Trikannad; Sruthi Vellanki; Sanjay Muttineni; Hira Cheema; Syed Naqvi; Sasya Dronavalli; Samer Al Hadidi; Sharmilan Thanendrarjan; Maurizio Zangari; Frits van Rhee; Aniko Szabo; Rajshekar Chakraborty; Meera Mohan; Carolina Schinke
Affiliations1. Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, USA; 2. Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, USA; 3. University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, USA; 4. Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, USA; 5. Myeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, USA; 6. Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, USA; 7. Division of Division of Hematology Oncology, Columbia University Irving Medical Center, New York, USA; 8. Division of Lymphoma and Myeloma, University of Texas MD Anderson Cancer, Houston, USA
139
days
Persistence of M-proteins detected by mass spectrometry
AuthorsDavid L. Murray; Jonathan Coker; Taxiarchis Kourelis; Angela Dispenzieri; Mindy Kohlhagen; Surendra Dasari; Maria Willrich
Affiliations1. Division of Clinical Biochemistry & Immunology, Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, USA; 2. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, USA; 3. Division of Quantitative Health Sciences, Mayo Clinic, Rochester, USA
54
days
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma
AuthorsAlexandra D. Dreyfuss; Joachim Yahalom; Sridevi Rajeeve; Alexander M. Lesokhin; Gunjan L. Shah; Heather J. Landau; Maximilian Merz; Michael Scordo; Andriy Derkach; David Nemirovsky; Harper Hubbeling; Gustav Cederquist; Zachary R. Moore; Sergio A. Giralt; Sham Mailankody; Saad Z. Usmani; Brandon S. Imber; Hamza Hashmi
Affiliations1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA; 2. Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA; 3. Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; 4. Division of Epidemiology and Biostatistics, Department of Research, Memorial Sloan Kettering Cancer Center, New York, USA; 5. Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
76
days
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia
AuthorsMahnoor Fatima; Sudhesh Kumar; Momna Warraich; Kristen McCullough; Aref Al-Kali; Hassan B. Alkhateeb; Kebede H. Begna; Abhishek Mangaonkar; Antoine N. Saliba; Mark R. Litzow; William Hogan; Mithun V. Shah; Mrinal M. Patnaik; Animesh Pardanani; Talha Badar; James Foran; Jeanne Palmer; Cecilia Arana Yi; Ayalew Tefferi; Naseema Gangat
Affiliations1. Division of Hematology, Mayo Clinic, Rochester, USA; 2. Division of Hematology, Mayo Clinic, Jacksonville, USA; 3. Division of Hematology, Mayo Clinic, Scottsdale, USA
86
days
Patterns and perceptions of supplement use among patients with plasma cell disorders
AuthorsMaria A. Malik; Eliana Schach; Yan Leyfman; Andriy Derkach; Francesca Castro; Jorge Arturo Hurtado Martinez; Ana M. Sahagun Sanchez Aldana; Patricia Alejandra Flores Perez; Jennifer M. Ahlstrom; Jay R. Hydren; Saad Z. Usmani; Jun J. Mao; Susan Chimonas; Urvi A. Shah
Affiliations1. Department of Medicine, NYU Grossman School of Medicine, New York, USA; 2. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, USA; 3. Department of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, USA; 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA; 5. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; 6. HealthTree Foundation, Lehi, USA; 7. Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, USA; 8. Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, USA
82
days
Dynamics of in vivo immune remodeling in Ph + all patients receiving frontline ponatinib and blinatumomab therapy
AuthorsNadia Peragine; Michela Ansuinelli; Giulia Radice; Mariangela Di Trani; Maria Stefania De Propris; Giada Almici; Marina Parisi; Maria Paola Martelli; Daniele Mattei; Erika Borlenghi; Federico Fazio; Daniele Vallisa; Sabina Chiaretti; Anna Guarini; Robin Foà
Affiliations1. Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy; 2. Division of Hematology and Bone Marrow Transplant, Azienda Ospedaliera-Universitaria (AOU) Policlinico-S. Marco, Catania, Italy; 3. Dipartimento di Medicina e Chirurgia, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy; 4. Division of Hematology, Santa Croce e Carle Hospital, Cuneo, Italy; 5. Hematology, ASST Spedali Civili, Brescia, Italy; 6. Hematology, Azienda Ospedaliera-Universitaria SS. Arrigo e Biagio e Cesare Arrigo, Alessandria, Italy; 7. Hematology Unit, Department of Oncology and Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
80
days
Hair bulb and oral mucosa DNA for prompt germline testing in hematologic neoplasms
AuthorsFerran Balbastre-Úbeda; Sara Torres-Esquius; Maria Gabarrós-Subirà; Francisco Beas; Jordi Leno-Colorado; Cristina Sanchez-Morales; Tzu Hua Chen-Liang; Susana Urban-Giral; Meritxell Tena-Alegre; Ana María Hurtado; María Jesús Casas-Tio; Ana María Garrido; Pamela Acha; Adoración Blanco; Francesc Solé; Mónica Del Rey; María Díez-Campelo; David Valcárcel; Maria Julia Montoro; Andrés Jerez
Affiliations1. Myeloid Malignancies Research Group, Vall d’Hebron Institute of Oncology (VHIO), Hematology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 2. Clinical and Molecular Genetics Area, Vall d’Hebron Hospital Medicine Genetics Group, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain; 3. Hematology Department, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Murcia, Spain; 4. Group of Genetics, Molecular Pathology and Rare Diseases, Health Sciences Faculty, Universidad Católica de Murcia, Guadalupe, Spain; 5. MDS Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Badalona, Spain; 6. Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain
109
days
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity
AuthorsKenneth JC Lim; Melinda Tan; Ricardo Parrondo; Saurabh Chhabra; Christoph Schaefers; Katharine Dooley; Andre De Menezes Silva Corraes; Malvika Gupta; Darin Carabenciov; Morie Gertz; Lisa Hwa; Stephens Haily; Prashant Kapoor; Taxiarchis Kourelis; Rahma Warsame; Joselle Cook; Moritz Binder; Nadine Abdallah; Saurabh Zanwar; P. Leif Bergsagel; Udit Yadav; Erin Wiedmeier-Nutor; Susan Geyer; Sikander Ailawadhi; Rafael Fonseca; Shaji Kumar; Anastasia Zekeridou; Yi Lin
Affiliations1. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA; 2. Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; 3. Department of Haematology, The Alfred Hospital, Melbourne, Australia; 4. Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, USA; 5. Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, USA; 6. Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days